Biotech Values

[genisi]

I'm guessing they tested for pK via blood levels for BID vs. TID dosing long ago, but Tibotec/JNJ started that C208 trial only in Oct. 07 to evaluate dosing and backbones (we've mentioned it on a different occasion #msg-27821995). Perhaps pK results were not close enough or maybe they weren't in a hurry thinking competition (with preferable dosing) is still a couple of years behind. Now, and better late than never, data indicate that telaprevir will ultimately be a twice daily drug.

On different interferons: SGP is testing its PI in a Peg-Intron background only. I don't think SGP will test Roche's Pegasys, but C208 trial makes me think that boceprevir, if dosed with Pegasys would also yield better results like telaprevir did.